XALKORI for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 269 adverse event reports in the FDA FAERS database where XALKORI was used for Lung neoplasm malignant.
Most Reported Side Effects for XALKORI
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 125 | 23.4% | 53 | 12 |
| Death | 90 | 16.8% | 90 | 6 |
| Lung neoplasm malignant | 67 | 12.5% | 27 | 8 |
| Nausea | 64 | 12.0% | 5 | 4 |
| Diarrhoea | 43 | 8.0% | 0 | 4 |
| Fatigue | 32 | 6.0% | 2 | 2 |
| Vomiting | 29 | 5.4% | 3 | 6 |
| Constipation | 27 | 5.1% | 1 | 3 |
| Oedema peripheral | 27 | 5.1% | 4 | 2 |
| Off label use | 26 | 4.9% | 10 | 2 |
| Decreased appetite | 20 | 3.7% | 1 | 2 |
| Dizziness | 18 | 3.4% | 0 | 3 |
| Pneumonia | 18 | 3.4% | 7 | 9 |
| Neoplasm malignant | 17 | 3.2% | 1 | 0 |
| Dysgeusia | 15 | 2.8% | 0 | 0 |
Other Indications for XALKORI
Non-small cell lung cancer (70)
Neoplasm malignant (20)
Lung cancer metastatic (12)
Non-small cell lung cancer metastatic (10)
Lung adenocarcinoma (6)
Tracheal cancer (5)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)